Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2017 · 10-K
Revenue$0.00$0.00no prior Q4 2016 on file Net Income-$2.55M-$2.55MN/M vs Q4 2016 EPS Diluted-$0.32-$0.32N/M vs Q4 2016 Operating Income-$2,548,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Mar 31, 2017 · filed Jun 29, 2017 · 90 d after period end